BriaCell Therapeutics Corp Warrant
BCTXW
BCTXW was delisted on the 26th of February, 2026.
0 hedge funds and large institutions have $0 invested in BriaCell Therapeutics Corp Warrant in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 7 closing their positions.
6.27% less ownership
Funds ownership: 6.27% → 0% (-6.3%)
100% less funds holding
Funds holding: 7 → 0 (-7)
100% less capital invested
Capital invested by funds: $8.31K → $0 (-$8.31K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.54K |
| 2 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$2.35K |
| 3 |
HF
HRT Financial
New York
|
-$1K |
| 4 |
VF
Virtu Financial
New York
|
-$1K |
| 5 |
LGM
L1 Global Manager
Melbourne,
|
-$370 |
BCTXW Hedge Fund Activity: Q1 2026 in Review
0 of the 8,198 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXW) for Q1 2026, worth a combined $0 — down 100% from $8.31K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BCTXW and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $3.54K sold.
- 0 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXW) as of Q1 2026, down from 7 in Q4 2025.
- Funds reported $0 of BriaCell Therapeutics Corp Warrant stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new BriaCell Therapeutics Corp Warrant positions in Q1 2026 and 7 closed out, a net change of -7 holders.
- The largest BriaCell Therapeutics Corp Warrant seller in Q1 2026 was Susquehanna International Group, an estimated $3.54K sold.
Based on aggregated 13F filings for Q1 2026.